Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 49
Filter
2.
New Microbes New Infect ; 52: 101110, 2023 Mar.
Article in English | MEDLINE | ID: covidwho-2280687
3.
Travel Med Infect Dis ; 52: 102550, 2023.
Article in English | MEDLINE | ID: covidwho-2247501
4.
Travel Med Infect Dis ; 52: 102535, 2023.
Article in English | MEDLINE | ID: covidwho-2245079
5.
Travel Med Infect Dis ; 51: 102488, 2022 Oct 31.
Article in English | MEDLINE | ID: covidwho-2239807
6.
BMC Gastroenterol ; 22(1): 433, 2022 Oct 13.
Article in English | MEDLINE | ID: covidwho-2064737

ABSTRACT

BACKGROUND: Liver diseases post-COVID-19 vaccination is extremely rare but can occur. A growing body of evidence has indicated that portal vein thrombosis, autoimmune hepatitis, raised liver enzymes and liver injuries, etc., may be potential consequence of COVID-19 vaccines. OBJECTIVES: To describe the results of a systematic review for new-onset and relapsed liver disease following COVID-19 vaccination. METHODS: For this systematic review, we searched Proquest, Medline, Embase, PubMed, CINAHL, Wiley online library, Scopus and Nature through the Preferred Reporting Items for Systematic Reviews and Meta Analyses PRISMA guideline for studies on the incidence of new onset or relapsed liver diseases post-COVID-19 vaccination, published from December 1, 2020 to July 31, 2022, with English language restriction. RESULTS: Two hundred seventy-five cases from one hundred and eighteen articles were included in the qualitative synthesis of this systematic review. Autoimmune hepatitis (138 cases) was the most frequent pathology observed post-COVID-19 vaccination, followed by portal vein thrombosis (52 cases), raised liver enzymes (26 cases) and liver injury (21 cases). Other cases include splanchnic vein thrombosis, acute cellular rejection of the liver, jaundice, hepatomegaly, acute hepatic failure and hepatic porphyria. Mortality was reported in any of the included cases for acute hepatic failure (n = 4, 50%), portal vein thrombosis (n = 25, 48.1%), splanchnic vein thrombosis (n = 6, 42.8%), jaundice (n = 1, 12.5%), raised liver enzymes (n = 2, 7.7%), and autoimmune hepatitis (n = 3, 2.2%). Most patients were easily treated without any serious complications, recovered and did not require long-term hepatic therapy. CONCLUSION: Reported evidence of liver diseases post-COIVD-19 vaccination should not discourage vaccination against this worldwide pandemic. The number of reported cases is relatively very small in relation to the hundreds of millions of vaccinations that have occurred and the protective benefits offered by COVID-19 vaccination far outweigh the risks.


Subject(s)
COVID-19 Vaccines , COVID-19 , Hepatitis, Autoimmune , Liver Failure, Acute , Venous Thrombosis , Humans , Chronic Disease , COVID-19/epidemiology , COVID-19/prevention & control , COVID-19 Vaccines/adverse effects , Hepatitis, Autoimmune/complications , Hepatitis, Autoimmune/etiology , Liver Failure, Acute/complications , Vaccination/adverse effects , Venous Thrombosis/complications , Venous Thrombosis/etiology
7.
8.
Pathogens ; 11(7)2022 Jun 21.
Article in English | MEDLINE | ID: covidwho-1964047

ABSTRACT

In October 2021, a case of acute hepatic failure without any known cause was identified in the United States of America. Upon further investigation, other children aged 1-6 years were reported to have the same liver failure, and some of them were positive for adenovirus 41 type F. On 21 April 2022, the Centers for Disease Control and Prevention (CDC) released an alert after 74 cases were identified in United Kingdom (UK) between 5 and 8 April in children below 10 years of age, some of whom were also found to be positive for SARS-CoV-2. All the patients showed symptoms such as vomiting, diarrhea, jaundice, and abdominal pain. The patients' liver enzymes were remarkably increased. A total of 650 cases had been reported from 33 countries as of 27 May 2022, among which 222 cases were reported in the UK alone. No connection with SARS-CoV-2 or its vaccine has been found so far. However, the suspected cause is adenovirus, including its genomic variations, because its pathogenesis and laboratory investigations have been positively linked. Until further evidence emerges, hygiene precautions could be helpful to prevent its spread.

10.
Ann Med Surg (Lond) ; 80: 104062, 2022 Aug.
Article in English | MEDLINE | ID: covidwho-1914134

ABSTRACT

Despite the fact that various therapeutic compounds are being investigated, there is still a scarcity of effective and reliable therapeutic regimens to treat COVID-19. Ever since the COVID-19 pandemic, a diversity of traditional herbal treatments has been investigated to cure infected people, either alone or in conjunction with mainstream pharmaceuticals, with encouraging outcomes. In this article, we look at the latest research on the usage of natural products to alleviate the severity of COVID-19. To determine the activity of the natural products, act against SARS-CoV-2 to various targets like Mpro, ACE-II, papain-like, chymotrypsin-like proteases, and some antiviral targets. The processes underlying this preventative or therapeutic action are also examined. We used PubMed, Scopus, Google Scholar, and the WHO site to perform our review. The anti-SARS-CoV-2 impacts of various herbal extracts and purified compounds may be mediated via direct prevention of viral replication or entrance. Interestingly, certain items might avert SARS-CoV-2 from infecting human cells by blocking the ACE-2 protein or the serine protease TMPRRS2. Natural products have also been stated to suppress proteins intricate in the virus life cycle, like papain-like and chymotrypsin-like proteases. To conclude, natural products can be used alone or in combination as remedies or treatments for COVID-19. In addition, their compositions may provide insight into the development of effective and reliable antiviral drugs.

11.
EMBO Mol Med ; 14(8): e16287, 2022 08 08.
Article in English | MEDLINE | ID: covidwho-1912283

ABSTRACT

Africa carries a high burden of infectious diseases. Every year, millions of Africans contract tuberculosis, malaria, and many other diseases. Malaria kills hundreds of thousands of children under the age of five years annually. More than 11,000 people died during the 2014-2016 Ebola outbreak in West Africa; still, occasional cases of Ebola, as well as monkeypox, periodically appear in the Democratic Republic of Congo. Since most of the African countries gained their independence during the 1960s, the continent has relied heavily on the outside world for diagnostics, medicines, vaccines, personal protective equipment, and other medical supplies. Africa consumes nearly 25% of the globally produced vaccines but imports 99% and 95% of its vaccines and medicines, respectively. The 55 African countries were not able to ensure the health of 1.3 billion Africans during the COVID-19 pandemic but had to rely on other global initiatives and other countries for help and support. However, the pandemic and the shortage of vaccines may have been the much-needed trigger for this situation to change. "When misfortunes increase, they erase each other." Naguib Mahfouz (1911-2006).


Subject(s)
COVID-19 , Hemorrhagic Fever, Ebola , Malaria , Vaccines , Africa/epidemiology , COVID-19/epidemiology , COVID-19/prevention & control , Child , Child, Preschool , Hemorrhagic Fever, Ebola/epidemiology , Humans , Malaria/epidemiology , Pandemics/prevention & control
13.
J Infect Public Health ; 15(7): 788-799, 2022 Jul.
Article in English | MEDLINE | ID: covidwho-1895226

ABSTRACT

BACKGROUND: As the therapeutic regimens against the COVID-19 remain scarce, the microRNAs (miRNAs) can be exploited to generate efficient therapeutic targets. The miRNAs have been found to play pivotal roles in the several regulatory functions influencing the prognosis of viral infection. The miRNAs have a prospective role in the up and down regulation of the ACE2 receptors. This review examines the clinical applications, as well as the possible threats associated with the use of miRNAs to combat the deleterious consequences of SARS-CoV-2 infection. METHODOLOGY: This article was compiled to evaluate how the miRNAs are involved in the SARS-CoV-2 pathogenesis and infection, and their potential functions which could help in the development of therapeutic targets against the COVID-19. The sources of the collected information include the several journals, databases and scientific search engines such as the Google scholar, Pubmed, Science direct, official website of WHO, among the other sites. The investigations on the online platform were conducted using the keywords miRNA biogenesis, miRNA and ACE2 interaction, therapeutic role of miRNAs against SARS-CoV-2 and miRNA therapy side effects. RESULTS: This review has highlighted that the miRNAs can be exploited to generate potential therapeutic targets against the COVID-19. Changes in the miRNA levels following viral replication are an essential component of the host response to infection. The collection and modification of miRNA modulates may help to minimize the deleterious consequences of SARS-CoV-2 infection, such as by controlling or inhibiting the generation of cytokines and chemokines. The degradation of viral RNA by the cellular miRNAs, along with the reduced expression of ACE2 receptors, can substantially reduce the viral load. Specific miRNAs have been found to have an antiviral influence, allowing the immune system to combat the infection or forcing the virus into a latency stage. CONCLUSION: This review summarizes several studies revealing the involvement of miRNAs in diverse and complex processes during the infection process of SARS-CoV-2. The miRNAs can substantially reduce the viral load by degradation of viral RNA and reduced expression of ACE2 receptors, besides mitigating the deleterious consequences of the exaggerated secretion of cytokines. Extensive investigations need to be done by the scientific community to utilize the miRNA based strategies for the development of effective therapeutic targets against the COVID-19.


Subject(s)
COVID-19 Drug Treatment , MicroRNAs , Angiotensin-Converting Enzyme 2 , Cytokines , Humans , MicroRNAs/genetics , MicroRNAs/metabolism , MicroRNAs/therapeutic use , RNA, Viral/genetics , SARS-CoV-2
15.
Ann Med Surg (Lond) ; 79: 103985, 2022 Jul.
Article in English | MEDLINE | ID: covidwho-1885601

ABSTRACT

From many decades, emerging infections have threatened humanity. The pandemics caused by different CoVs have already claimed and will continue to claim millions of lives. The SARS, Ebola, MERS epidemics and the most recent emergence of COVID-19 pandemic have threatened populations across borders. Since a highly pathogenic CoV has been evolved into the human population in the twenty-first century known as SARS, scientific advancements and innovative methods to tackle these viruses have increased in order to improve response preparedness towards the unpredictable threat posed by these rapidly emerging pathogens. Recently published review articles on SARS-CoV-2 have mainly focused on its pathogenesis, epidemiology and available treatments. However, in this review, we have done a systematic comparison of all three CoVs i.e., SARS, MERS and SARS-CoV-2 along with Ebola and Zika in terms of their epidemiology, virology, clinical features and current treatment strategies. This review focuses on important emerging RNA viruses starting from Zika, Ebola and the CoVs which include SARS, MERS and SARS-CoV-2. Each of these viruses has been elaborated on the basis of their epidemiology, virulence, transmission and treatment. However, special attention has been given to SARS-CoV-2 and the disease caused by it i.e., COVID-19 due to current havoc caused worldwide. At the end, insights into the current understanding of the lessons learned from previous epidemics to combat emerging CoVs have been described. The travel-related viral spread, the unprecedented nosocomial outbreaks and the high case-fatality rates associated with these highly transmissible and pathogenic viruses highlight the need for new prophylactic and therapeutic actions which include but are not limited to clinical indicators, contact tracing, and laboratory investigations as important factors that need to be taken into account in order to arrive at the final conclusion.

16.
Int. j. morphol ; 39(4): 1231-1233, ago. 2021.
Article in English | WHO COVID, LILACS (Americas) | ID: covidwho-1863068

ABSTRACT

SUMMARY: Consecutive waves of the COVID-19 pandemic made teaching and learning tasks harder for veterinary anatomy faculties and students worldwide compared to the prepandemic scenario. Online teaching has been triggered across several countries as a precautionary measure against COVID-19. Educational institutions are looking towards online learning platforms to continue educating the students, as many veterinary institutes have been shut down due to COVID-19. As with most teaching methods, online learning also has its own set of positives and negatives. This letter aims to highlight the pros and cons of online veterinary anatomy education in the COVID-19 pandemic period. In conclusion, prepandemic teaching has been effective and adaptable for veterinary anatomy students for a better learning process, whereas online teaching has major cons over a few pros.


RESUMEN: Las oleadas consecutivas de la pandemia COVID-19 han dificultado las tareas de enseñanza y aprendizaje para las facultades de anatomía veterinaria y para los estudiantes de todo el mundo en comparación con el escenario prepandémico. Se ha activado en varios países la enseñanza en línea como medida de precaución durante la crisis de la COVID-19. Las instituciones educacionales están buscando plataformas de aprendizaje en línea para continuar la enseñanza de los alumnos, debido a que muchos institutos veterinarios se han cerrado. Como ocurre con la mayoría de los métodos de enseñanza, el aprendizaje en línea también tiene su propio conjunto de aspectos positivos y negativos. Este estudio tiene como objetivo resaltar las ventajas y desventajas de la educación en anatomía veterinaria en línea en el período de la pandemia de la COVID-19. En conclusión, la enseñanza prepandemia ha sido eficaz y adaptable para los estudiantes de anatomía veterinaria para lograr un proceso mejor de aprendizaje, mientras que la enseñanza en línea tiene mayores desventajas.


Subject(s)
Humans , Education, Distance , COVID-19 , Anatomy, Veterinary/education , Pandemics , SARS-CoV-2
18.
19.
Ann Med Surg (Lond) ; 78: 103737, 2022 Jun.
Article in English | MEDLINE | ID: covidwho-1821120

ABSTRACT

Despite many nations' best efforts to contain the so-called COVID-19 pandemic, the emergence of the SARS-CoV-2 Omicron strain (B.1.1.529) has been identified as a serious concern. After more than two years of COVID-19 pandemic and more than a year of worldwide vaccination efforts, the globe will not be free of COVID-19 variants such as Delta and Omicron variants. According to current statistics, the Omicron variant has more than 30 mutations when contrasted to other VOCs such as Alpha (B.1.1.7), Beta (B.1.351), and Delta (B.1.617.2). High numbers of changes, particularly in the spike protein (S-Protein), raise worries about the virus's capacity to resist pre-existing immunity acquired by vaccination or spontaneous infection and antibody-based therapy. The Omicron variant raised international concerns, resuming travel bans and coming up with many questions about its severity, transmissibility, testing, detection, and vaccines efficiency against it. Additionally, inadequate health care infrastructures and many immunocompromised individuals increase the infection susceptibility. The current status of low vaccination rates will play a significant role in omicron spreading and create a fertile ground for producing new variants. As a result, this article emphasizes the mutational changes and their consequences. In addition, the potential preventing measures have been examined in detail.

20.
Hum Vaccin Immunother ; 18(5): 2068883, 2022 11 30.
Article in English | MEDLINE | ID: covidwho-1819753

ABSTRACT

Since commencement of COVID-19 pandemic, several SARS-CoV-2 variants have emerged amid containment efforts via vaccination. The Delta variant (B.1.617.2), discovered in October 2020, was designated as a VOC by the WHO on May 11, 2021. The enhanced transmissibility of Delta variant has been associated with critical mutations such as D614G, L452R, P681R, and T478K in the S-protein. The increased affinity of the S-protein and ACE2 has been postulated as a key reason for decreased vaccine efficacy. As per evidence, the Delta variant possesses increased transmissibility and decreased vaccine efficacy compared to other VOCs like Alpha and Beta. This has led to concerns regarding the acquisition of novel mutations in the Delta variant and outbreaks in vulnerable communities, including vaccinated people. In this mini-review of Delta variant, we have explained its evolution and characteristics, the impact of spike mutations on infectivity and immune evasion, and measures to combat future outbreaks.


Subject(s)
COVID-19 , SARS-CoV-2 , Angiotensin-Converting Enzyme 2 , COVID-19/prevention & control , Humans , Membrane Glycoproteins , Mutation , Pandemics , Peptidyl-Dipeptidase A , SARS-CoV-2/genetics , Spike Glycoprotein, Coronavirus/genetics , Viral Envelope Proteins
SELECTION OF CITATIONS
SEARCH DETAIL